These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18829780)

  • 1. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J; Wong KK; O'Connell C; Warren AE
    Pediatrics; 2008 Oct; 122(4):e828-34. PubMed ID: 18829780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications.
    Thomas PE; Carlo WF; Decker JA; Cannon BC; Kertesz NJ; Friedman RA; Kim JJ
    Arch Pediatr Adolesc Med; 2011 Feb; 165(2):166-70. PubMed ID: 21300657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paediatricians' decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder.
    Chow SJ; Sciberras E; Gillam LH; Green J; Efron D
    Child Care Health Dev; 2014 May; 40(3):301-8. PubMed ID: 23445484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 10. Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuro-educational approach.
    Monastra VJ
    Int J Psychophysiol; 2005 Oct; 58(1):71-80. PubMed ID: 15927296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E
    CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
    [No Abstract]   [Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (For).
    Isaacs D
    J Paediatr Child Health; 2006 Sep; 42(9):544-7. PubMed ID: 16925542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in medications administered in schools.
    McCarthy AM; Kelly MW; Johnson S; Roman J; Zimmerman MB
    J Sch Nurs; 2006 Apr; 22(2):102-7. PubMed ID: 16563033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulant medication in pre-school children in New South Wales.
    Eysbouts Y; Poulton A; Salmelainen P
    J Paediatr Child Health; 2011 Dec; 47(12):870-4. PubMed ID: 21658150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.
    Warren AE; Hamilton RM; Bélanger SA; Gray C; Gow RM; Sanatani S; Côté JM; Lougheed J; LeBlanc J; Martin S; Miles B; Mitchell C; Gorman DA; Weiss M; Schachar R
    Can J Cardiol; 2009 Nov; 25(11):625-30. PubMed ID: 19898693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic screening in children with attention-deficit hyperactivity disorder.
    Mahle WT; Hebson C; Strieper MJ
    Am J Cardiol; 2009 Nov; 104(9):1296-9. PubMed ID: 19840580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH; Donnelly C
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract]   [Full Text] [Related]  

  • 19. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (Against).
    Efron D
    J Paediatr Child Health; 2006 Sep; 42(9):548-51. PubMed ID: 16925543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled study of autonomic nervous system function in adults with attention-deficit/hyperactivity disorder treated with stimulant medications: results of a pilot study.
    Schubiner H; Hassunizadeh B; Kaczynski R
    J Atten Disord; 2006 Nov; 10(2):205-11. PubMed ID: 17085631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.